These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23174177)

  • 21. [Malignant pleural mesothelioma].
    Nishiwaki Y
    Gan To Kagaku Ryoho; 2003 May; 30(5):589-94. PubMed ID: 12795087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
    Karatkevich D; Deng H; Gao Y; Flint E; Peng RW; Schmid RA; Dorn P; Marti TM
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
    Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
    Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
    Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
    Kim ST; Park JY; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
    Jpn J Clin Oncol; 2010 Nov; 40(11):1031-6. PubMed ID: 20534685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
    Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
    Mujoomdar AA; Tilleman TR; Richards WG; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):352-5. PubMed ID: 20653100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
    Giovannetti E; Zucali PA; Assaraf YG; Leon LG; Smid K; Alecci C; Giancola F; Destro A; Gianoncelli L; Lorenzi E; Roncalli M; Santoro A; Peters GJ
    Br J Cancer; 2011 Nov; 105(10):1542-53. PubMed ID: 21970874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.
    Pinton G; Manente AG; Daga A; Cilli M; Rinaldi M; Nilsson S; Moro L
    Mol Cancer; 2014 Oct; 13():227. PubMed ID: 25277603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
    Agatsuma T; Koizumi T; Yasuo M; Urushihata K; Tsushima K; Yamamoto H; Hanaoka M; Fukushima M; Honda T; Kubo K
    Jpn J Clin Oncol; 2010 Dec; 40(12):1180-3. PubMed ID: 20603247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
    Mutlu H; Gündüz S; Karaca H; Büyükçelik A; Cihan YB; Erden A; Akca Z; Coşkun HS
    Med Oncol; 2014 Aug; 31(8):74. PubMed ID: 24958517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
    Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
    Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
    Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
    Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
    Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
    J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
    Green J; Dundar Y; Dodd S; Dickson R; Walley T
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005574. PubMed ID: 17253564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
    Garcia-Carbonero R; Paz-Ares L
    Eur J Surg Oncol; 2006 Aug; 32(6):676-81. PubMed ID: 16616827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
    Opitz I; Kestenholz P; Lardinois D; Müller M; Rousson V; Schneiter D; Stahel R; Weder W
    Eur J Cardiothorac Surg; 2006 Apr; 29(4):579-84. PubMed ID: 16495068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.